Dutch spin-off from a Dutch university of technology and an institute for nanotechnology is developing and commercializing a technology platform allowing for intradermal delivery of pharmaceutical compounds. Ceramic nanoporous microneedle arrays (npMNAs) are an important part of this innovative concept. The npMNAs are integrated into a patch providing easy and safe usage by patient and/or healthcare worker.
The SME has lab facilities at a bio science park and employs 5 people.
An ISO certified producer of high-tech glass and ceramic materials in The Netherlands is manufacturing the nanoporous MNAs, according to the company's patented process. The portfolio of co-developments and in-house development projects relate to a wide range of drug delivery applications. Various animal studies have been completed for delivery of small molecules, peptides and vaccines, including a challenge study with influenza vaccine. The company is now ready for its first clinical study in healthy volunteers: a peptide formulation will be delivered by the npMNA technology.
The company has ample experience in international and national partnerships with industries and universities, including grant projects and co-developments.
The company is looking for partners for technical cooperation: the Dutch company will make this technology available to a partner that provides the (proprietary) drug compound / vaccine. Partners interested in licensing or technical cooperation and forming a consortium to apply for a grant like Horizon 2020 in the framework of a co-development agreement are sought.